(2-Bromophenyl)thiourea is a **chemical compound** that is often used in research due to its interesting properties and applications.
Here's a breakdown:
**What it is:**
* **Structure:** It's composed of a thiourea group (NH2-C(=S)-NH2) attached to a phenyl ring (a six-membered carbon ring with alternating single and double bonds) with a bromine atom at the 2-position (meaning it's attached to the carbon atom next to the point where the thiourea group is attached).
* **Appearance:** It's typically a white to off-white solid.
**Why it's important for research:**
(2-Bromophenyl)thiourea has been used in a variety of research areas, primarily due to its:
* **Biological activity:** It has shown **antimicrobial**, **antifungal**, and **anti-inflammatory** properties. This makes it potentially useful for developing new medicines and therapies.
* **Ligand properties:** It can act as a **ligand**, a molecule that binds to a metal ion or another molecule. This property is crucial for studying metal complexes and their potential applications in catalysis, materials science, and bioinorganic chemistry.
* **Crystallization properties:** It can form **crystals** with unique properties, which makes it suitable for studying crystal growth and solid-state physics.
* **Synthetic intermediate:** It can be used as a starting material for synthesizing other compounds with desired properties.
**Specific research areas where it's used:**
* **Medicinal chemistry:** Researching its potential as a new drug candidate for various diseases.
* **Coordination chemistry:** Studying the formation and properties of metal complexes with (2-bromophenyl)thiourea.
* **Materials science:** Exploring its potential use in developing new materials with specific properties.
* **Organic synthesis:** Investigating its use as a building block in the synthesis of other organic molecules.
**It's important to note:**
* The research on (2-bromophenyl)thiourea is ongoing, and its full potential is still being explored.
* Safety precautions must be taken when handling this compound, as it can be harmful if ingested or inhaled.
In summary, (2-bromophenyl)thiourea is a versatile compound that has sparked research interest in various fields due to its unique chemical properties and potential applications in medicine, materials science, and organic synthesis.
ID Source | ID |
---|---|
PubMed CID | 2735618 |
CHEMBL ID | 1534587 |
CHEBI ID | 120635 |
SCHEMBL ID | 2357864 |
SCHEMBL ID | 11693811 |
Synonym |
---|
thiourea, (2-bromophenyl)- |
thiourea,(2-bromophenyl)- |
1-(2-bromophenyl)-2-thiourea |
n-(2-bromophenyl)thiourea |
MLS000835024 |
smr000461640 |
CHEBI:120635 |
(2-bromophenyl)thiourea |
EN300-87357 |
NCGC00246708-01 |
1-(2-bromophenyl)thiourea |
A829826 |
2-bromophenylthiourea |
5391-30-0 |
AKOS005202770 |
HMS2794J18 |
FT-0611599 |
QIGMVYSPXPXCPN-UHFFFAOYSA-N |
2-bromophenyl thiourea |
SCHEMBL2357864 |
SCHEMBL11693811 |
|a-tosyl-(2,3-difluorobenzyl)isocyanide |
thiourea, (bromophenyl)- |
CHEMBL1534587 |
Q27208765 |
DTXSID80202186 |
mfcd00041146 |
CCG-256086 |
o-bromophenylthiourea |
STL510539 |
F19866 |
CS-16214 |
CS-0093548 |
Class | Description |
---|---|
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 100.0000 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
TDP1 protein | Homo sapiens (human) | Potency | 11.5821 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 22.1969 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 0.1000 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 7.0795 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |